Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT07031154
A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer
Sponsor: The First Affiliated Hospital of Xiamen University
Conditions
Adebrelimab Apatinib Non-Small Cell Lung Cancer
Interventions
Adebrelimab Apatinib
Updated 1 time since 2025 Last updated: Jun 12, 2025 Started: Jun 30, 2025 Primary completion: Feb 1, 2027 Completion: Feb 1, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Adebrelimab and Apatinib and is currently actively recruiting participants. The First Affiliated Hospital of Xiamen University leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- The First Affiliated Hospital of Xiamen University
Data source: The First Affiliated Hospital of Xiamen University
For direct contact, visit the study record on ClinicalTrials.gov .